| Literature DB >> 18455394 |
Tim Sparey1, Pravien Abeywickrema, Sarah Almond, Nick Brandon, Noel Byrne, Alister Campbell, Pete H Hutson, Marlene Jacobson, Brian Jones, Sanjeev Munshi, Danette Pascarella, Andrew Pike, G Sridhar Prasad, Nancy Sachs, Melanie Sakatis, Vinod Sardana, Shankar Venkatraman, Mary Beth Young.
Abstract
The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18455394 DOI： 10.1016/j.bmcl.2008.04.020
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823